EUVIMEDEUVIMED entdecken
Crossref

Rationally Designed Ru(II) Complex with Dual Type I/II ROS Generation for Hypoxia-Tolerant Photodynamic Therapy in Melanoma

Xueling Li, Yue Zhang, Yan Huang, Weixia Qing iD, Yong Wang iD, Pengtao Ma iD

Inorganic Chemistry · 2026

DOI: 10.1021/acs.inorgchem.6c04054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inorganic Chemistry, 2026. Verfasst von Xueling Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry and Molecular Sciences, Henan University, Kaifeng475004, P. R. China. Hauptthemen laut MEDLINE: Photochemotherapy, Ruthenium, Reactive Oxygen Species, Coordination Complexes. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Henan Provincial Science and Technology Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The hypoxic tumor microenvironment of melanoma imposes a critical limitation on conventional type II photodynamic therapy (PDT), relying on oxygen for the generation of cytotoxic reactive oxygen species (ROS). To overcome this challenge, a donor-π-acceptor (D-π-A) bis-terpyridine ruthenium(II) complex, Ru(tpy)2TT, was rationally designed and synthesized to enable dual type I/II ROS generation. The ROS production efficiency was quantitatively evaluated in B16 murine melanoma cells, and the antitumor efficacy was assessed in a syngeneic C57BL/6N mouse melanoma model. Upon photoactivation at 500 nm, Ru(tpy)2TT efficiently generated both superoxide anion (type I ROS) and singlet oxygen (type II ROS). Intratumoral administration followed by localized irradiation resulted in an 80% reduction in tumor volume after 10 days, with no observed systemic toxicity or off-target effects. These findings demonstrate that Ru(tpy)2TT circumvents hypoxia-induced PDT resistance in melanoma via hypoxia-tolerant and oxygen-dependent ROS pathways, establishing its potential as a targeted precision antitumor agent. Furthermore, this work provides a generalizable molecular design strategy for developing hypoxia-tolerant PDT agents for refractory melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhotochemotherapyRutheniumReactive Oxygen SpeciesCoordination ComplexesPhotosensitizing AgentsAntineoplastic AgentsMelanoma, ExperimentalDrug DesignAnimalsMiceMice, Inbred C57BLMolecular StructureDrug Screening Assays, AntitumorCell Proliferation

Substanzen

RutheniumReactive Oxygen SpeciesCoordination ComplexesPhotosensitizing AgentsAntineoplastic Agents

Autor:innen und Institutionen

  • College of Chemistry and Molecular Sciences, Henan University, Kaifeng475004, P. R. China.
  • School of Basic Medical Science, Henan University, Kaifeng475004, P. R. China.

ORCID-Profile: Weixia Qing, Yong Wang, Pengtao Ma

Förderung

  • Henan Provincial Science and Technology Research Project

Zitieren

APA

Li, X., Zhang, Y., Huang, Y., Qing, W., Wang, Y., & Ma, P. (2026). Rationally Designed Ru(II) Complex with Dual Type I/II ROS Generation for Hypoxia-Tolerant Photodynamic Therapy in Melanoma. Inorganic Chemistry. https://doi.org/10.1021/acs.inorgchem.6c04054

Vancouver

Li X, Zhang Y, Huang Y, Qing W, Wang Y, Ma P. Rationally Designed Ru(II) Complex with Dual Type I/II ROS Generation for Hypoxia-Tolerant Photodynamic Therapy in Melanoma. Inorganic Chemistry. 2026. doi:10.1021/acs.inorgchem.6c04054

BibTeX
@article{Li2026,
  author = {Li, Xueling and Zhang, Yue and Huang, Yan and Qing, Weixia and Wang, Yong and Ma, Pengtao},
  title = {Rationally Designed Ru(II) Complex with Dual Type I/II ROS Generation for Hypoxia-Tolerant Photodynamic Therapy in Melanoma},
  journal = {Inorganic Chemistry},
  year = {2026},
  doi = {10.1021/acs.inorgchem.6c04054}
}
Kostenlos starten →